Tempus AI and USC Keck Medicine announced a partnership that will integrate Tempus’s AI‑driven diagnostics and genomic profiling into USC’s clinical workflows across more than 1.5 million patient visits annually at USC Norris Comprehensive Cancer Center, Keck Hospital, Verdugo Hills, and other USC‑affiliated sites.
The collaboration is built on four pillars: clinical testing integration, trial matching via the TIME Trial Program, AI‑driven care‑gap pathways, and joint research and co‑development. These pillars aim to streamline patient care, accelerate trial enrollment, close care gaps, and translate research into validated diagnostics.
By linking its data‑rich platform to a large academic medical system, Tempus gains access to a vast patient dataset that will enhance its AI models and create new revenue streams through shared services and research. The partnership positions Tempus as a key player in precision medicine and expands its reach into Southern California.
Tempus reported Q1 2025 revenue of $255.7 million, up 75.4% YoY, and Q4 2025 revenue of $367.2 million, up 83.0% YoY, while continuing to post net losses of $68.0 million and $54.2 million respectively. Gross profit rose to $155.2 million in Q1 and $237.7 million in Q4, reflecting improving margins in Diagnostics and Data & Applications segments. The company is guiding for $1.59 billion in revenue for 2026, representing roughly 25% growth from the full‑year 2025 total of $1.3 billion.
Vasiliki Anest, PhD, Chief Innovation Officer at Keck, said, "By working closely with Tempus, and in collaboration with clinical, research and operational leaders across USC, we are aligning research, clinical care, and innovation priorities that put the patient first." Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus, added, "We're excited to embark on this collaboration with USC, an institution that shares our commitment to advancing health care through data and technology." Eric Lefkofsky, CEO of Tempus, noted, "The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year‑over‑year operating leverage."
The partnership is expected to accelerate Tempus's data acquisition, enhance AI model accuracy, and open new revenue opportunities through clinical services and research collaborations. It also strengthens Tempus's competitive position against other AI‑driven precision‑medicine providers and supports the company's long‑term strategy to democratize access to personalized care.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.